About this eBook

Despite major advances in precision oncology, key challenges remain: identifying individuals at elevated cancer risk, enabling even earlier detection, predicting therapeutic response, understanding resistance mechanisms, and monitoring recurrence. By expanding the scope of liquid biopsy beyond nucleic acids to include proteins, researchers can capture functional biological signals that reflect both tumor biology and host response.

Through a series of impactful, peer-reviewed studies, the ebook “Protein biomarkers across the cancer continuum” explores how high-dimensional proteomics can be applied across the whole cancer continuum— from risk stratification and early detection to treatment selection, response monitoring, toxicity assessment, and relapse prediction.

Discover how proteins measured in minimally invasive biofluids are helping researchers address some of the most important questions in translational oncology:

• Which individuals are at increased risk of developing cancer?

• Can disease be detected before clinical presentation?

• Which molecular features are associated with therapeutic response?

• What biological mechanisms drive treatment resistance?

• Can treatment-related toxicity be predicted and understood mechanistically?

• Which circulating signatures are associated with disease recurrence?